Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression.Nucleic acids research · 2021
   Article
2. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
   Article
3. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.Annals of Indian Academy of Neurology
   Review
4. Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury.eNeuro
   Article

Corrections and comments

• Commented on by
  Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides-Reply.2016
• Comment on
  Synthetic Nucleic Acids and Treatment of Neurological Diseases.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as